NCT06866964View on ClinicalTrials.gov

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

January 31, 2031

Conditions
Germ Cell TumorTesticular Cancer
Interventions
DRUG

Low-dose ASA

81 mg by mouth daily for 26 weeks

Trial Locations (2)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte

All Listed Sponsors
collaborator

Atrium Health Wake Forest Baptist

OTHER

lead

Wake Forest University Health Sciences

OTHER

NCT06866964 - A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy | Biotech Hunter | Biotech Hunter